Genflow Biosciences Share Discussion Threads

[moneymunch] 18/1/2024 22:09

Revatis SA

Innovation in cellular therapy

Revatis is a Spin Off from the University of Liège, dedicated to regenerative medicine and cell therapy. Revatis is based on the scientific discoveries of Prof. D. Serteyn and Dr J. Ceusters and has solid intellectual property and exceptional know-how.

Revatis has a patented technology for obtaining multipotent stem cells from a muscle micro-biopsy. This technology is available for clinical applications in veterinary medicine and for research in human medicine.

In veterinary medicine, Revatis aims to produce autologous stem cells for therapeutic use in horses and companion animals. In human medicine, Revatis is positioning itself as a supplier of personalized stem cells for banking, research, organ-on-a-chip and 3D bioprinting.



.....

Exo Biologics

Unlocking the Potential of Exosomes: The Next Frontier of Nanomedicine
Exosomes are nanometer-sized vesicles containing bioactive molecules secreted by cells. They can be used for the targeted delivery of therapeutic agents.


Exosomes are specific extracellular vesicles that carry RNA, Lipids, and protein messengers, naturally released by various cells. They induce and modulate distinct effects on targeted cells. Depending on their cellular origin, exosomes can also be loaded with specific bioactive molecules, and they have a potency and targeting ability.

EXOB-001, Our Lead Product Candidate
EXOB-001 Investigational Medical Product (IMP) consists of a sterile suspension of allogeneic extracellular vesicles (EVs) derived from cultured human umbilical cord mesenchymal stromal cells (hMSCs).

Human MSCs are characterized by their ability to, among other things, secrete various growth factors and cytokines that modulate the immune system and promote tissue repair and regeneration.

[moneymunch] 18/1/2024 22:07

GenFlow Biosciences

1,413 followers
7h

GenFlow Biosciences (LSE: GENF) (OTCQB: GENFF) is thrilled to announce its partnership with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants 🧬

"The two research programs are a part of a broader innovation partnership that the Walloon Government has launched, dedicated to Advanced Therapy Medicinal Products (ATMPs). The partnership boasts a substantial budget of 81 million euros, a mix of 60% public funding and 40% private contributions from various companies, spread over three years. This initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia and the Public Service of Wallonia, representing a significant commitment to advancing medical research and development in the region."

Read more about the exciting new venture here:

#ageing #longevity #healthspan #smallcap

[steg] 18/1/2024 22:01

Could be an amazing recovery story this year when you consider we were just over 12p at ipo time 2 years ago, since then massive progress, patents, multiple new projects, up and coming human trial in NASH, FDA meeting scheduled, solid funding for the years ahead, mice trial data coming soon, cash in the bank, CEO owns over 40% of company and the list goes on and on, definitely not ramping as this is all factual and public knowledge. My only speculation is that we will very soon see institutional buying making the free float very very tight as Eric has made it clear and has now proven time and time again that he is very capable of raising funds via non dilutive funding grants. I can’t help but to feel that if 12p was fair two years ago with the huge progress now made and long term financial security of the business in what is fast becoming the hottest world wide market for all to see surely fair value is now 12p to 36p. This could be a life changing share for those prepared to have some patience all of course in my humble opinion as they say, meantime best of luck to investors prepared to hold long term

[moneymunch] 18/1/2024 19:54

12 months since a crucial patent application, not just for Genflow but a breakthrough for gene therapy and longevity research according to Eric, which could add massive value if awarded. It can take up to 2 years for approval, but the US Patent Office can award within 12 months if accelerated, and so news at anytime which would be truly transformational for all concerned. Gla :-)

"Genflow has expanded its intellectual property portfolio with a provisional patent application focusing on the SIRT6 gene editing. If granted, this patent could mark a significant breakthrough in gene therapy and longevity research."



1.20230018934

METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS

US - 19.01.2023
Int.Class
A61K 48/00
Appl.No 17865688

Applicant GENFLOW BIOSCIENCES SRL

Inventor Eric LEIRE

Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.

[northeast14] 18/1/2024 17:55

Lawson27- definitely be in a few papers and hopefully Eric will do an interview with proactive investors

[luckyabbeygale] 18/1/2024 16:21

From my stockwatch I have noticed an unusual amount of losses being cut on other stocks.
I wonder if any of that is for investing here.

[lawson27] 18/1/2024 16:01

No doubting we shall get mentioned in a few financials tomorrow

[northeast14] 18/1/2024 15:57

Tomorrow should be interesting also after people read this later

[kubera369] 18/1/2024 15:50

People just have to be crazy selling now as this is only going one way now as they transport Genflow to the launch pad and set the burners on fire

[moneymunch] 18/1/2024 15:47

Still very much under the radar and still cheap as chips, the timing of today's news missed by many and so just the start of some serious UPside, especially as more positive newsflow is very likely in the near term pipeline. Gl :-)

[luckyabbeygale] 18/1/2024 15:18

I guess a lot of us hold different shares here and did not do the right thing in offloading them after seeing that news to buy as many as we can here.

I offloaded some but not enough. I never good at that sort of thing.

[moneymunch] 18/1/2024 14:38

Eric said that he’s expecting a crazy money buy out as soon as the FDA recognise ageing as a disease and he expects it soon, and that’s why he listed in both the UK and US to get the interest of the big pharma above all over companies who work in similar fields. He also said that something similar had happened to him before in another company and the warning signs are there for him once again. Holding tight!

[davealders] 18/1/2024 14:28

I personally don't see the point in looking at the share price. It's a long, long way to go until we reach the heights of before. I'm here for one reason and one reason only.... BUYOUT.
With what's going on here at Genflow, I see a buyout as a massive possibility within the next 2 years and if it takes longer then I'm fully prepared to wait.
Eric will want north of 40p plus per share and with the bottomless bank accounts of the big Pharma companies it will be nothing to them.
Wouldn't surprise me if talks or even references to a buyout has even happen.
Finally looking great again here, news wise.
Good luck all.
Thanks

[moneymunch] 18/1/2024 14:12

We're still awaiting Final reports from the 4 invivo studies to be published, which must be imminent, and should be very well received. Gla :-)

September 2023



The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.

These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.

[kubera369] 18/1/2024 13:51

A rebate lolOr a real re rate It's so overdue and I expect Eric and Genflow to deliver fireworks on the expected news flow coming in any day and throughout this year.The U.S interest should now also build up along with institutional investments.Tiny McapSmall Free Float Unprecedented demand on a hot sector Genflow = the only longevity company holding may patents and the only one listed in the UK and has first mover advantage in Europe Bring on the Re Rate !!!

[northeast14] 18/1/2024 13:42

Fully expect to see a rebate now

[moneymunch] 18/1/2024 13:29

Along way indeed Northeast, but plenty more to come from Eric and Co to get Genflow in full investor focus and market appreciation....Gl :-)

[luckyabbeygale] 18/1/2024 13:11

Those not in may not be able to afford to live forever. As this is one of the companys involved in the latest research that will help abolish old age in around ten years time.

[northeast14] 18/1/2024 12:46

Along way to fill the gap back to 12p!
Hopefully the start of a huge recovery
GLA

[moneymunch] 18/1/2024 12:22

Let's hope Eric has a wad of positive newsflow to deliver in the coming days and weeks...Gla holders...On and UP!!! ;-)

[kubera369] 18/1/2024 12:17

Potential buyout/acquisition target Sitting duck for any pharma predator now and fully funded for years to come SP at under 2p Bargain !!!This year is the year

[moneymunch] 18/1/2024 12:16

Lol...about time too, and much more to come...Genflow is all set for a great year ahead. Gla holders;-)

[lawson27] 18/1/2024 12:15

Nice news, onwards and upwards, GLA

[kubera369] 18/1/2024 12:14

This is mind blowing news Wow!!!On top of more positive news incoming from Genflow Loads going on now with Sirt6 and Anti Ageing This company is just off radar and extremely undervalued Keep buying I say